Home LiteratureArticle Details
PMID: 3994898 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

An investigation of the cause of accumulation of verapamil during regular dosing in patients.

British journal of clinical pharmacology ·Vol. 19 ·No. 4 ·1985-04-00 ·Pages 512-6

Schwartz JB, Abernethy DR, Taylor AA, Mitchell JR

Abstract

The accumulation of verapamil during regular dosing conditions was studied. Plasma concentrations of verapamil (V) and norverapamil (NV) were measured as were urinary concentrations of verapamil, norverapamil, and four other N- and O-dealkylated metabolites in nine patients after an initial single dose and after chronic oral verapamil administration to steady-state plasma concentrations. Indocyanine green (ICG) clearance was determined immediately prior to the initial verapamil dose and prior to the verapamil washout from regular dosing. An approximately two-fold accumulation of V had occurred during regular dosing. The area under the plasma concentration-time curve (AUC1) after the first dose was 417.4 +/- 276.7 ng ml-1 h (mean +/- s.d.) and increased to 786.5 +/- 54 ng ml-1 h (P less than 0.01) during one dosage interval at steady-state (AUCss). NV also tended to accumulate from an AUC1 of 552.6 +/- 411 to an AUCss 668.7 +/- 332 ng ml-1 h (P less than 0.09). The ratio of AUC-V to AUC-NV was unchanged. The verapamil elimination half-life (t 1/2) increased from 8.4 +/- 4.2 to 12.0 +/- 3.6 h (P less than 0.01) whereas the norverapamil t 1/2 was unchanged. ICG clearance was unchanged. Urinary excretion of NV increased slightly but the ratio of urinary V/NV concentrations was not significantly altered nor was the ratio of four other metabolites to verapamil or the ratio of the combined o-demethylated to the N-dealkylated metabolites.(ABSTRACT TRUNCATED AT 250 WORDS)

MeSH Terms
Adult Aged Dealkylation Female Half-Life Humans Indocyanine Green Kinetics Male Middle Aged Time Factors Verapamil/administration & dosage,analogs & derivatives,blood,metabolism
Chemicals
norverapamil Verapamil Indocyanine Green
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Schwartz J B
Abernethy D R
Taylor A A
Mitchell J R
References (12)
12 references, click to expand
  1. Differences between the plasma indocyanine green disappearance rates of normal men and women.
    Proc Soc Exp Biol Med. 1975 Dec;150(3):612-7 PMID: 1208580
  2. Cardiovascular action of verapamil in the dog with particular reference to myocardial contractility and atrioventricular conduction.
    Cardiovasc Res. 1976 NOV;10(6):623-32 PMID: 991162
  3. Clinical pharmacokinetics of calcium ion antagonists.
    Clin Invest Med. 1980;3(1-2):13-7 PMID: 7471537
  4. Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment.
    Klin Wochenschr. 1980 Sep 15;58(18):919-25 PMID: 7206587
  5. Simultaneous determination of verapamil and its seven metabolites by high-performance liquid chromatography.
    J Chromatogr. 1981 Mar 13;222(3):507-11 PMID: 7228962
  6. Verapamil and norverapamil determination in human plasma by gas-liquid chromatography using nitrogen-phosphorus detection: application to single-dose pharmacokinetic studies.
    Pharmacology. 1984;29(5):264-8 PMID: 6494236
  7. Verapamil kinetics in normal subjects and patients with coronary artery spasm.
    Clin Pharmacol Ther. 1981 Nov;30(5):644-52 PMID: 7297023
  8. Reduced verapamil clearance during long-term oral administration.
    Clin Pharmacol Ther. 1981 Nov;30(5):701-6 PMID: 7297027
  9. Prediction of steady-state verapamil plasma concentrations in children and adults.
    Clin Pharmacol Ther. 1982 Aug;32(2):172-81 PMID: 7094504
  10. Prolongation of verapamil elimination kinetics during chronic oral administration.
    Am Heart J. 1982 Aug;104(2 Pt 1):198-203 PMID: 7102502
  11. Application of stable labelled drugs in clinical pharmacokinetic investigations.
    Clin Pharmacokinet. 1982 Nov-Dec;7(6):490-507 PMID: 6819104
  12. Verapamil disposition kinetics in chronic atrial fibrillation.
    Clin Pharmacol Ther. 1981 Jul;30(1):44-51 PMID: 7237897
Article Info
Journal
British journal of clinical pharmacology
Abbr.
Br J Clin Pharmacol
ISSN
0306-5251
Published
1985-04-00
Pages
512-6
Language
English
Region
England
NLM ID
7503323
PMCID
PMC1463828
Subset
IM
Grants
NIADDK NIH HHS · AM-32050 · United States
NCRR NIH HHS · RR-00350 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com